Stockreport

ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.

ImmunoPrecise Antibodies Ltd.  (IPA) 
PDF Programs to be Driven Through Patented AI Technology and Advanced Proprietary B Cell PlatformsPartnership advances next-generation ADCs and bispecific antibodies to addr [Read more]